General Information of Drug Combination (ID: DCGB4W8)

Drug Combination Name
Arfolitixorin BHV-0223
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Arfolitixorin   DMIXMYK BHV-0223   DMBLM5H
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 5.86
Bliss Independence Score: 5.86
Loewe Additivity Score: 7.82
LHighest Single Agent (HSA) Score: 7.84

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)